Healthcare Industry News: Genoptix
News Release - October 5, 2010
Anacor Pharmaceuticals Appoints Geoffrey M. Parker as Chief Financial OfficerPALO ALTO, Calif.--(Healthcare Sales & Marketing Network)-- Anacor Pharmaceuticals today announced the appointment of Geoffrey M. Parker as Senior Vice President and Chief Financial Officer. Mr. Parker will be responsible for managing the company’s finance operations as well as its business development and investor relations functions.
Mr. Parker served as a consultant to Anacor from December 2009 to his current appointment as Chief Financial Officer. From July 2009 to July 2010, Mr. Parker served in a consulting capacity as the Chief Business Officer of InteKrin Therapeutics, a privately held biopharmaceutical company in Los Altos, California. From 1997 to April 2009, Mr. Parker was a Vice President, then Managing Director and finally Partner at the global investment banking and securities firm Goldman Sachs Group, Inc., leading their West Coast Healthcare Investment Banking practice during this time. Mr. Parker also served in various capacities with Goldman Sachs Group, Inc. from 1990 to 1995 and 1986 to 1988. From 1995 to 1997, Mr. Parker was Vice President at Feibusch & Co., a venture capital firm in Larkspur, California. Mr. Parker is currently a member of the board of directors of Genoptix, Inc., a specialized laboratory service provider and ChemoCentryx, Inc., a clinical-stage privately held biopharmaceutical company. Mr. Parker received an A.B. from Dartmouth College in Engineering Sciences and Economics and an M.B.A. from Stanford University.
About Anacor Pharmaceuticals
Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its chemistry platform. Anacor has discovered and is developing five clinical compounds, including its three lead programs: AN2690, a topical antifungal for the treatment of onychomycosis; AN2728, a topical anti-inflammatory PDE-4 inhibitor for the treatment of psoriasis and GSK 2251052, or GSK ‘052 (formerly referred to as AN3365), a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria, which has been optioned for development by GlaxoSmithKline under the companies’ research and development agreement. In addition, Anacor is developing AN2718 as a topical antifungal product candidate for the treatment of onychomycosis and skin fungal infections, and AN2898 as a topical anti-inflammatory product candidate for the treatment of psoriasis and atopic dermatitis. For more information visit www.anacor.com.
This press release may contain forward-looking statements, including statements regarding Mr. Parker’s appointment as an officer of Anacor, that relate to future events and involve known and unknown risks, uncertainties and other factors that could cause actual levels of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking statements. These statements reflect the views of Anacor as of the date of this press release with respect to future events and, except as required by law, it undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this press release.
Source: Anacor Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.